Videos

Ian W. Flinn, MD, PhD, discusses what factors go into his decision to use polatuzumab plus bendamustine and rituximab in certain patients with relapsed/refractory diffuse large B-cell lymphoma.

Srdan Verstovsek, MD, PhD, highlights what future research in myeloproliferative neoplasms looks to examine.

Daniel J George, MD, shares his advice for community oncologists and discusses unmet needs when treating patients with advanced renal cell carcinoma.

Dr Daniel J George talks about the quality-of-life outcomes from the CHECKMATE 9ER and how different metastatic scenarios might affect treatment selection.

Dr Daniel J George reviews long term follow up data from the CHECKMATE 9ER and the implications of the data in the treatment paradigm for patients with advanced renal cell carcinoma.

Dr Daniel J George reviews long term follow up data from the CHECKMATE 9ER and the implications of the data in the treatment paradigm for patients with advanced renal cell carcinoma.

An expert oncologist explains how to calculate a patient’s risk status and provides an overview of front-line treatment options for patients with advanced renal cell carcinoma and discusses which factors are considered when choosing appropriate treatment.

Daniel J. George, MD, describes the case of a 68-year-old woman with advanced renal cell carcinoma.

Focused discussion on the selection of first-line therapy for advanced clear cell renal cell carcinoma based on sites of metastasis.

Expert panelists consider the importance of quality of life when selecting first-line treatment regimens for patients with advanced clear cell renal cell carcinoma.

Hagop M. Kantarjian, MD, discusses what experts should know regarding ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Dr Scott Tykodi muses on how he would alter treatment for a patient with advanced clear cell RCC after side effects develop.

Drs Tannir and Tykodi share their differing views on the effect an IO and a TKI agent have when combined for advanced clear cell RCC treatment.

Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.

Eytan M. Stein, MD, provides an overview of myelodysplastic syndrome, including risk factors, symptoms, and diagnosis.

Nitin Jain, MD, explains the key takeaways from multiple discussions on acute lymphoblastic leukemia which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.

Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.

Opening the discussion on the management of BPDCN, an expert panel consisting of two hematologist-oncologists and a pathologist, considers the causes, incidence and diagnostic approach to this rare disease.

Bradley A. McGregor, MD, discusses new trials of intensified combination regimens for frontline treatment of patients with intermediate- or poor-risk advanced renal cell carcinoma.

Melhem Solh, MD, discusses his research on post-transplant outcomes of patients with TP53-mutant acute myeloid leukemia and myelodysplastic syndrome.

Closing out her discussion on the management of recurrent metastatic endometrial cancer, Bhavana Pothuri, MD, highlights ongoing clinical trials and novel treatment modalities.

Bhavana Pothuri, MD provides a perspective on the management of immune-related adverse events that can be seen in patients treated for recurrent metastatic endometrial cancer, as well as a focused discussion on the conversations she has with her patients.

Focusing on patients with recurrent metastatic endometrial cancer, an expert oncologist identifies factors that help inform the selection of second-line targeted therapy.

Centering discussion on safety and efficacy data from the GARNET trial, Bhavana Pothuri, MD, reflects on the role of dostarlimab therapy in patients with recurrent metastatic endometrial cancer.

Comprehensive insight to the systemic treatment armamentarium available to patients with metastatic EC.

Expert perspective on the presentation of endometrial cancer, followed by advice on providing optimal workup and diagnosis.

Expert oncologist Bhavana Pothuri, MD, reviews the diagnosis and treatment of a 64-year-old woman who presents and recurs with mismatch repair-deficient (dMMR) endometrial cancer (EC).

Chenyu Lin, MD, discusses the significance of a 10-year follow up of a study of patients who underwent allogeneic stem cell transplant with the novel cell therapy omidubicel.

Shared insight on optimal dosing strategies with first-line tyrosine kinase inhibitor and immunotherapy combinations for patients with advanced clear cell renal cell carcinoma.

Sumanta Pal, MD, an expert hematologist/oncologist, evaluates the combination of cabozantinib + nivolumab as first-line therapy for advanced clear cell renal cell carcinoma.